Vaccines against Chlamydia: approaches and progress
- PMID: 9572058
- DOI: 10.1016/s1357-4310(98)01232-5
Vaccines against Chlamydia: approaches and progress
Abstract
Infections of the eye and genital tract with the bacterium Chlamydia trachomatis are a major cause of morbidity worldwide and are costly to treat. Development of a vaccine capable of protecting against infection or severe disease presents special challenges but would be the most effective long-term option for control of chlamydial disease. Progress has been made in understanding protective and pathological immune mechanisms in these infections, and a number of potential vaccine candidates have been developed.
Similar articles
-
Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection.Vaccine. 1995 Aug;13(11):1023-32. doi: 10.1016/0264-410x(95)00017-u. Vaccine. 1995. PMID: 8525685
-
Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine.Vaccine. 2015 Apr 27;33(18):2159-66. doi: 10.1016/j.vaccine.2015.02.055. Epub 2015 Mar 1. Vaccine. 2015. PMID: 25738816 Free PMC article.
-
Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge.Infect Immun. 2001 Oct;69(10):6240-7. doi: 10.1128/IAI.69.10.6240-6247.2001. Infect Immun. 2001. PMID: 11553566 Free PMC article.
-
Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates.Virulence. 2016;7(1):11-22. doi: 10.1080/21505594.2015.1111509. Epub 2015 Nov 18. Virulence. 2016. PMID: 26580416 Free PMC article. Review.
-
Chlamydia trachomatis infection: incidence, health costs and prospects for vaccine development.J Reprod Immunol. 2000 Aug;48(1):47-68. doi: 10.1016/s0165-0378(00)00069-3. J Reprod Immunol. 2000. PMID: 10996382 Review.
Cited by
-
Immunological memory in B-cell-deficient mice conveys long-lasting protection against genital tract infection with Chlamydia trachomatis by rapid recruitment of T cells.Immunology. 2001 Feb;102(2):199-208. doi: 10.1046/j.1365-2567.2001.01167.x. Immunology. 2001. PMID: 11260325 Free PMC article.
-
Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.Vaccine. 2011 May 12;29(21):3802-10. doi: 10.1016/j.vaccine.2011.03.027. Epub 2011 Mar 21. Vaccine. 2011. PMID: 21421002 Free PMC article.
-
Infectivity of Chlamydia trachomatis serovar LGV but not E is dependent on host cell heparan sulfate.Infect Immun. 2001 Feb;69(2):968-76. doi: 10.1128/IAI.69.2.968-976.2001. Infect Immun. 2001. PMID: 11159992 Free PMC article.
-
Aerosolized Non-viral Nucleic Acid Delivery in the Vaginal Tract of Pigs.Pharm Res. 2016 Feb;33(2):384-94. doi: 10.1007/s11095-015-1796-x. Epub 2015 Oct 30. Pharm Res. 2016. PMID: 26514579
-
Characterization of murine dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in Chlamydia muridarum antigen presentation and induction of protective immunity.Infect Immun. 2008 Jun;76(6):2392-401. doi: 10.1128/IAI.01584-07. Epub 2008 Mar 24. Infect Immun. 2008. PMID: 18362126 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical